Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 1 sale; 210 institutions reported holding it in 13F filings for Q3 2026, worth $2.58B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $1.96B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $334.2K in total
- 1
- 13F holdersQ3 2026, +11 vs. previous quarter
- 210
- 13F valueReported value at the end of Q3 2026
- $2.58B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $6.94M
- −23.2% year over year
- Net income, FY2025
- -$212.4M
- No comparable prior period
- Free cash flow, FY2025
- -$200.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $212.4M (3060.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 16.2M
- Shares sold short
- Change
- −1.11M
- −6.4% vs. previous
- Days to cover
- 12.77
- At average daily volume
Superinvestors holding IMNM, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding IMNM at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Immunome Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 11 | 4 days | Higgins JackChief Scientific Officer | SSale | −13.2K | $25.32 | −$334.2K | −16.9%65.0K after | 10b5-1 |
| Aug 12, 2026 (view filing)5:47 PM ET | Aug 10-11 | 2 days | Barchas IsaacDirector | SSale | −72.4K | $26.21 | −$1.90M | −100.0%0 after | 2 lots10b5-1 |
| Aug 12, 2026 (view filing)5:47 PM ET | Aug 12 | Same day | Barchas IsaacDirector | SSale | −11.0K | $27.25 | −$301.1K | −10.7%92.2K after | 10b5-1 |
| Aug 10, 2026 (view filing)4:10 PM ET | Aug 6-7 | 4 days | Barchas IsaacDirector | SSale | −36.1K | $26.06 | −$940.5K | −33.3%72.4K after | 2 lots10b5-1 |
| Aug 6, 2026 (view filing)6:30 PM ET | Aug 4 | 2 days | Horn KinneyCHIEF BUSINESS OFFICER | SSale | −90.6K | $25.09 | −$2.27M | −100.0%0 after | 10b5-1 |
| Jul 9, 2026 (view filing)5:38 PM ET | Jul 7 | 2 days | Horn KinneyCHIEF BUSINESS OFFICER | SSale | −1.09K | $25.00 | −$27.3K | −100.0%0 after | 10b5-1 |
| Jul 7, 2026 (view filing)7:02 PM ET | Jul 6-7 | 1 day | Barchas IsaacDirector | SSale | −100.0K | $24.13 | −$2.41M | −48.0%108.5K after | 2 lots10b5-1 |
| Jul 7, 2026 (view filing)5:42 PM ET | Jul 2 | 5 days | Lechleider RobertChief Medical Officer | SSale | −55.0K | $22.62 | −$1.24M | −77.7%15.8K after | 3 lots10b5-1 |
| Jul 2, 2026 (view filing)8:31 PM ET | Jun 30-Jul 2 | 2 days | Barchas IsaacDirector | SSale | −201.1K | $21.85 | −$4.39M | −49.1%208.5K after | 3 lots10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25 | 4 days | Lechleider RobertChief Medical Officer | SSale | −55.0K | $19.85 | −$1.09M | −77.7%15.8K after | 2 lots10b5-1 |
Top 10 13F holders, Q3 2026
See all 210 holdersThe largest institutional positions in Immunome Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 20,211,392 | $434.7M | 0.31% | +534,509+2.7% | Added |
| FMR LLC | 17,036,641 | $366.5M | 0.02% | +49,088+0.3% | Added |
| BlackRock, Inc. | 8,929,024 | $192.1M | 0.00% | +123,532+1.4% | Added |
| Wellington Management Group LLP | 6,041,333 | $129.9M | 0.02% | +831,117+16.0% | Added |
| Driehaus Capital Management LLC | 4,976,950 | $107.1M | 0.74% | +630,811+14.5% | Added |
| Vanguard Capital Management LLC | 4,882,131 | $105.0M | 0.00% | +330,842+7.3% | Added |
| Primecap Management Co | 4,644,821 | $99.9M | 0.06% | +63,390+1.4% | Added |
| State Street Corp | 4,490,152 | $96.6M | 0.00% | −1,004,473−18.3% | Reduced |
| Redmile Group, LLC | 4,363,064 | $93.8M | 6.87% | −548,526−11.2% | Reduced |
| Enavate Sciences GP, LLC | 3,613,799 | $77.7M | 27.79% | 00.0% | Unchanged |
Holders of 5% or more of IMNM
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Immunome Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 17.40%19.7M shares | +2.90 ppfrom 14.50% | Nov 14, 20244 filings | Aug 14, 2026 | SEC |
| FMR LLC | 13G/A | 15.00%13.1M shares | +7.90 ppfrom 7.10% | Feb 9, 20245 filings | Oct 7, 2025 | SEC |
| Immunome Aggregator, LP | 13D/A | 6.00%4.77M shares | – | Oct 12, 20232 filings | Feb 4, 2025 | SEC |
| Wellington Management Group LLP | 13G | 5.30%6.04M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.04%5.73M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |